Interval therapy for the treatment of tinnitus
AssigneeMERZ PHARMA GmbH & CO. KGaA
InventorsBarbara Ellers-Lenz, Tanja Rosenberg, Micael Althaus, Herman Russ, Hagen Kruger
Life of this patent
Estimating the term…
Abstract
The present invention relates to interval and/or maintenance therapy employing 1-amino-alkylcyclohexane derivatives (e.g., neramexane or a pharmaceutically acceptable salt thereof) for the treatment of an individual afflicted with tinnitus.
Claims23
1-17. (canceled)
A method of treating tinnitus in a subject in need thereof, comprising administering a therapeutically effective amount of a 1-amino-alkylcyclohexane derivative, wherein the therapeutically effective amount of the 1-amino-alkylcyclohexane derivative is administered daily for a first period of at least three (3) months, followed by a second period of at least one (1) month wherein the 1-amino-alkylcyclohexane derivative is administered at a dose which is 0-75% of the therapeutically effective dose.
A method of treating a 1-amino-alkylcyclohexane derivative responsive condition in a subject in need thereof, comprising administering a therapeutically effective amount of a 1-amino-alkylcyclohexane derivative, wherein the therapeutically effective amount of the 1-amino-alkylcyclohexane derivative is administered daily for a first period of at least three (3) months, followed by a second period of at least one (1) month wherein the 1-amino-alkylcyclohexane derivative is administered at a dose which is 0-75% of the therapeutically effective dose.
Dependencies are inferred from the claim text.